Quantum Genesis AI Corp. 8-K

What Happened

• Quantum Genesis AI Corp. (QTZM) announced on April 9, 2026 that it entered into a confirmatory Intellectual Property Assignment Agreement with its CEO, Naveen Kulkarni.
• The agreement assigns to the Company all rights in U.S. Patent Application Publication No. US20250146029A1, titled “Modified Polypeptides for Enzymatic Synthesis of Ibuprofen,” filed November 2, 2023 (published May 8, 2025). The assignment is effective as of the patent filing date (November 2, 2023).
• The Assignment Agreement formalizes and documents IP rights the Company previously acquired under an Asset Purchase Agreement dated February 21, 2023.

Key Details

• Agreement date: April 9, 2026; assignment effective date: November 2, 2023.
• Patent application: US20250146029A1 — “Modified Polypeptides for Enzymatic Synthesis of Ibuprofen” (filed 11/02/2023; published 05/08/2025).
• Assignor: Naveen Kulkarni (Company CEO). No purchase price or other financial terms disclosed in the filing.
• The Company will amend its FY2025 Form 10-K (fiscal year ended July 31, 2025) and its 10-Qs for the periods ended Oct 31, 2025 and Jan 31, 2026 to update disclosures reflecting the formalized IP rights.

Why It Matters

• The filing clarifies and documents Quantum Genesis’s ownership and enforcement rights over a patent application related to enzymatic synthesis of ibuprofen, removing uncertainty about who holds those IP rights.
• Clear ownership can be important for protecting potential commercial applications, licensing opportunities, or enforcing rights against infringement; the Company’s SEC filings will be updated to reflect this formalization.
• The 8-K does not disclose financial impacts or monetization plans, so investors should watch future filings or company communications for any valuation, licensing deals, or product-related announcements tied to this IP.